Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
$14.22
-$0.14(-3.78%)
At close: 4:00 PM EST
$14.22
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$2.60 - $17.49
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.60M
Market Cap
$1.64B
Enterprise Value$947.34M
Total Cash (Recent Filing)$343.99M
Total Debt (Recent Filing)$5.93M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Apr 01, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding109,819,570
10 Day Avg. Volume1,214,735
30 Day Avg. Volume1,602,197
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.56
Price to Sales (P/S)2.95
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue-1.42K
Enterprise Value/Gross Profit-45.85
Enterprise Value/Ebitda-6.16
Forecast
1Y Price Target
$21.67Price Target Upside52.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignCombined primary endpoint captures a wide range of clinically meaningful hypoglycemic events, increasing statistical power and the likelihood of detecting a treatment benefit.
Market OpportunityAddressable patient population is likely substantially larger than company estimates because patients with similar surgical histories share the same disease mechanism and may respond to the therapy, expanding commercial potential.
Safety ProfileTreatment has been generally well tolerated with no treatment-related serious adverse events reported, supporting a favorable risk-benefit view among clinicians and payers.
Bears Say
Evidence UncertaintyEarlier reliance on open-label studies introduces uncertainty about placebo effects and the reliability of trial outcomes, which could complicate regulatory review and clinician confidence.
Financial RiskHigh cash burn and a limited cash runway create material financing risk that may require dilutive capital raises or operational constraints.
Market SentimentElevated short interest around 13% may increase stock volatility and amplify downside pressure if negative news or financing needs emerge.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $2.60 and its highest was $17.49 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $1.64B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Apr 01, 2026 which is in 48 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.436 by $0.066.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.35.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 109,819,570 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.436. Following the earnings report the stock price went down -5.891%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.67 (52.39% Upside)
$21.67 (52.39% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $759.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 15.3%
Last 30 Days ▼ 15.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
274.21%
12-Months-Change
Fundamentals
Return on Equity
-56.52%
Trailing 12-Months
Asset Growth
44.68%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong financial performance and progress across multiple programs. However, there is a noted delay in the LUCIDITY trial enrollment, indicating some operational challenges. The urgency and unmet need in the PBH market further underscore the importance of avexitide's development.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$21.67
▲(52.39% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
7.43% Insiders
18.84% Mutual Funds
0.04% Other Institutional Investors
58.82% Public Companies and Individual Investors